Oral Peptide Delivery Advances

Overview

Oral administration is the preferred route for drug delivery — it is non-invasive, convenient, and promotes patient adherence. Yet peptides have historically been administered by injection because they face formidable barriers in the gastrointestinal (GI) tract: enzymatic degradation, poor membrane permeability, and low bioavailability. Overcoming these barriers is one of the most active areas of peptide pharmaceutical research.

The successful development of oral semaglutide (Rybelsus) demonstrated that clinically effective oral peptide delivery is achievable, marking a pivotal moment for the field. However, oral semaglutide's bioavailability remains low (approximately 0.4-1%), requiring high doses relative to the injectable formulation. Ongoing research aims to improve oral peptide absorption efficiency through a variety of engineering approaches, from permeation enhancers and enzyme inhibitors to nanoparticle carriers and device-based delivery systems.

Background

Barriers to Oral Peptide Absorption

Peptides face three principal obstacles in the GI tract:

1. Enzymatic degradation

The digestive system is designed to break down proteins and peptides into individual amino acids. Pepsin in the stomach, trypsin and chymotrypsin in the small intestine, and membrane-bound peptidases on the enterocyte brush border collectively create a gauntlet of proteolytic activity. Most unprotected peptides are degraded to inactive fragments within minutes of oral ingestion.

2. Poor membrane permeability

The intestinal epithelium is a selective barrier. Peptides are typically hydrophilic, charged at physiological pH, and larger than 500 Da — all properties that limit passive transcellular diffusion. The tight junctions between enterocytes further restrict paracellular transport. Only a small fraction of intact peptide molecules typically reaches the basolateral side of the epithelium.

3. First-pass metabolism

Peptides that successfully cross the intestinal epithelium face additional enzymatic degradation in the portal circulation and liver before reaching systemic circulation. This hepatic first-pass effect further reduces the fraction of orally administered peptide that reaches its target.

These barriers combine to yield oral bioavailabilities for most peptides below 1-2%, compared with near-complete bioavailability via subcutaneous injection.

Historical Context

The challenge of oral peptide delivery has been recognized since the discovery of insulin in the 1920s. Nearly a century of research has been dedicated to making insulin orally available, with limited success. The approval of oral semaglutide in 2019, using the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), represented the first broadly successful oral formulation of a peptide drug for a chronic condition.

Earlier successes existed in narrow contexts — cyclosporine A (a cyclic peptide immunosuppressant) achieved oral bioavailability through its inherent lipophilicity and cyclic structure, while desmopressin (a synthetic vasopressin analog) was formulated as an oral tablet despite very low bioavailability, compensated by dose adjustment.

Key Findings

Permeation Enhancers

Permeation enhancers transiently increase intestinal epithelial permeability, allowing peptides to cross the barrier via paracellular or transcellular routes.

• SNAC (sodium salcaprozate): Used in the oral semaglutide formulation. SNAC increases local gastric pH, protects semaglutide from pepsin degradation, and promotes transcellular absorption through a mechanism involving transient monomerization and enhanced lipophilicity. The tablet must be taken on an empty stomach with minimal water to concentrate the peptide-enhancer complex against the gastric mucosa.

• Sodium caprate (C10): A medium-chain fatty acid salt that transiently opens tight junctions. It has been studied in clinical trials for oral delivery of insulin and other peptides, with demonstrated absorption enhancement, though the window of permeability increase is brief.

• Cell-penetrating peptides (CPPs): Short cationic peptides (e.g., TAT, penetratin, oligoarginine) that facilitate membrane translocation. When conjugated to or co-administered with therapeutic peptides, CPPs can enhance transcellular transport. See Peptide Bioconjugation for conjugation strategies.

Enzyme Inhibitors

Co-administration of protease inhibitors can protect peptides from enzymatic degradation in the GI lumen:

• Aprotinin, bestatin, and soybean trypsin inhibitor: Classical protease inhibitors studied for oral peptide protection
• Bowman-Birk inhibitor: A soybean-derived serine protease inhibitor with broad-spectrum activity against trypsin and chymotrypsin
• Enteric coating: pH-sensitive polymer coatings that prevent tablet dissolution in the acidic stomach, releasing the peptide in the more neutral pH of the small intestine where pepsin is inactive

Nanoparticle and Microparticle Systems

Encapsulation of peptides in engineered carrier particles offers simultaneous protection from enzymes, enhanced mucoadhesion, and controlled release:

• PLGA nanoparticles: Poly(lactic-co-glycolic acid) particles that encapsulate peptides and protect them during GI transit. PLGA is biodegradable and FDA-approved for parenteral use, making it an attractive carrier material.
• Chitosan-based particles: Chitosan, a cationic polysaccharide, exhibits mucoadhesive properties and can transiently open tight junctions, combining carrier protection with permeation enhancement.
• Lipid nanoparticles: Self-nanoemulsifying drug delivery systems (SNEDDS) and solid lipid nanoparticles that enhance lymphatic uptake, potentially bypassing hepatic first-pass metabolism.
• pH-responsive hydrogels: Polymeric networks that swell at intestinal pH, releasing their peptide payload in the absorption-favorable environment of the small intestine.

Device-Based Delivery

Ingestible devices represent an emerging approach that bypasses the absorption barriers entirely by delivering peptides directly into or through the GI mucosa:

• Microneedle capsules: Ingestible capsules containing spring-loaded microneedles that inject peptide payloads directly into the gastric or intestinal wall upon arrival. The SOMA (self-orienting millimeter-scale applicator) device, developed at MIT, uses a weighted design to orient itself and inject a compressed insulin needle into the gastric mucosa.
• Mucoadhesive patches: Ingestible patches that adhere to the intestinal wall and create a localized high-concentration peptide reservoir against the epithelium, enhancing absorption while protecting from luminal enzymes.

Peptide Engineering

Modifying the peptide itself can improve oral stability and permeability:

• Cyclization: Constraining linear peptides into cyclic structures reduces conformational flexibility and protects against exopeptidases. Cyclosporine A's oral bioavailability is largely attributable to its cyclic structure.
• D-amino acid substitution: Replacing L-amino acids at protease-susceptible positions with their D-enantiomers renders the peptide resistant to most endogenous proteases.
• N-methylation: Methylating backbone amide nitrogens reduces hydrogen bonding potential and increases membrane permeability while also conferring protease resistance.
• PEGylation and lipidation: Conjugating polyethylene glycol or fatty acid chains can improve stability and membrane interactions. Semaglutide's C-18 fatty acid chain contributes to its albumin binding and extended half-life.

Current State

Oral semaglutide remains the most commercially significant oral peptide formulation, validating the SNAC permeation enhancer approach for GLP-1 receptor agonists. Several other oral peptide candidates are in clinical development:

• Oral insulin: Multiple formulations in Phase II/III trials using various enhancer and nanoparticle strategies. No product has yet achieved regulatory approval, though several have demonstrated meaningful postprandial glucose lowering.
• Oral octreotide (Mycapssa): An FDA-approved oral formulation of octreotide (a somatostatin analog) using the Transient Permeability Enhancer (TPE) technology, demonstrating that the oral peptide approach extends beyond GLP-1 agonists.
• Oral PTH analogs: Oral formulations of parathyroid hormone fragments for osteoporosis are in development.

Despite progress, oral peptide delivery remains inefficient. Most formulations achieve bioavailabilities in the low single digits, meaning the vast majority of the administered dose is wasted. This has cost implications and raises questions about GI tolerability of high-dose peptide formulations.

Future Directions

• AI-driven formulation optimization: Machine learning models predicting optimal combinations of enhancers, carriers, and peptide modifications for specific sequences
• Targeted intestinal delivery: Formulations designed to release peptide payloads at specific GI segments where absorption is most favorable
• Combination strategies: Layered formulations incorporating enzyme inhibitors, permeation enhancers, and nanoparticle carriers simultaneously
• Closed-loop ingestible devices: Smart capsules with sensors that detect local GI conditions and trigger peptide release at optimal times and locations
• Biologic-small molecule hybrids: Peptides engineered with small molecule-like properties (low molecular weight, lipophilicity, reduced hydrogen bonding) while retaining target specificity

Related Topics

• Peptide Bioconjugation — Conjugation strategies for improving peptide properties
• GLP-1 Research — The therapeutic area where oral peptide delivery has achieved its greatest success
• Peptides vs Small Molecules — Comparative pharmacology relevant to delivery challenges
• Future of Peptide Therapeutics — Broader trends shaping peptide drug development
• Compounding Pharmacy Peptides — Current formulation practices for peptide products